SEOUL-SEMICONDUCTOR
24.5.2017 09:09:07 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890) — On April 28, 2017, Seoul Semiconductor Europe GmbH (“Seoul”) filed a patent infringement claim in Germany at the District Court of Düsseldorf against Mouser Electronic Inc. (“Mouser), a global electronic components distributor, which it accused of selling Everlight LED products.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170524005266/en/
In its complaint, Seoul asserted that Everlight’s Mid-Power LED products are infringing Seoul’s patent rights. Seoul has sought a permanent injunction, damages, and recall and destruction of the allegedly infringing products.
The asserted patent serves to improve the light extraction performance of LED devices by enhancing internal-reflection efficiency, which has been widely used in mid-power and high-power LEDs.
This patent litigation is the second patent infringement litigation by Seoul or its affiliate affecting Everlight’s LED products. In March 2017, Seoul Semiconductor Co., Ltd. filed a patent infringement claim in Germany, accusing high-power LED products manufactured by Everlight as well as other LED manufacturers. These patent litigations underscore Seoul’s commitment to protecting its intellectual property rights against infringement, including products consisting of mid-power LEDs and high-power LEDs.
In addition to Seoul’s patent infringement actions, Everlight has been implicated in other patent infringement lawsuits as described below. Nam Ki-bum, Vice President of the Research Center at Seoul, said, “Several LED companies have grown rapidly in a short period of time despite a lack of valuable patent portfolios, which is like building a castle on quicksand. There is no underlying foundation for the company’s products. Seoul, however, has been investing 10% of its revenue in research and development for many years to develop innovative technology and strengthen our patent portfolio. To support a fair market that respects intellectual property rights, Seoul will continuously monitor and take action against alleged infringers in any countries where infringement occurs.”
* Reference [source: various media news articles]
| Plaintiff | Defendant | Business Relation | Patented Technology | Courts | State | Link | ||||||
| Nichia | WOFI Leuchten | Everlight subsidiary | phosphor | Düsseldorf District Court, Germany | Nichia won the suit in the court of first instance and the court ruled for an injunction |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | REGO-Lighting | Used a white LED tube light product by Everlight subsidiary Zenar | phosphor | Düsseldorf District Court, Germany | On Dec. 5, 2016, the appeals court confirmed patent infringement and ruled in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | phosphor | Düsseldorf District Court, Germany | On Oct. 24, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Tachibana Eletech and E&E Japan | Distributor of blue LEDs manufactured by Everlight in Japan | LED chip | Tokyo District Court, Japan | On Oct. 14, 2016, the court issued an oder ruled for an infringement in favor of Nichia. |
http://www.nichia.co.jp/en/about_nichia/2016 |
||||||
| Nichia | Mouser | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | On Oct. 7, 2016, the court granted a preliminary injunction. |
http://www.nichia.co.jp/en/about_nichia/2 |
||||||
| Nichia | Everlight | Everlight | LED Package | The U.S. District Court for the Eastern District of Texas | The Federal Circuit affirmed an infringement of Nichia’s patents. |
http://www.nichia.co.jp/en/about_nichia/20
http://www.ledinside.com/news/2017/5/nic |
||||||
| Nichia | EBV Elektronik GmbH & Co. KG and EBV Management GmbH (both “EBV“) | Distributor of Everlight products | phosphor | Düsseldorf District Court, Germany | Still in progress |
http://www.nichia.co.jp/en/about_nichia http://www.ledinside.com/press/2017/3/nichia _files_patent_infringement_lawsuit_against_ |
||||||
| Nichia | Everlight Electronics (China) and Beijing Ducheng Yiguang Electronic Devices Selling Center | Everlight subsidiary | phosphor | Beijing Intellectual Property Court, China | Still in progress |
http://www.nichia.co.jp/en/about_nichia |
||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | High Power LED | Düsseldorf District Court, Germany | Still in progress | |||||||
| Seoul Semiconductor | Mouser | Distributor of Everlight products | Mid Power LED | Düsseldorf District Court, Germany | On April 28, 2017, Seoul filed the lawsuit. | |||||||
About Seoul Semiconductor:
Seoul Semiconductor develops and commercializes light emitting diodes (LEDs) for automotive, general illumination, specialty lighting, and backlighting markets. As the fifth-largest LED manufacturer globally, Seoul Semiconductor holds more than 12,000 patents, offers a wide range of technologies, and mass produces innovative LED products such as Wicop – a simpler structured Package-Free LED which provides market leading color uniformity, cost savings at the fixture level with high lumen density and allows design flexibility; Acrich, the world's leading direct AC LED; Acrich MJT multi-junction technology; a proprietary family of high-voltage LEDs; NanoDriver Series – World’s Smallest 24W DC LED Drivers and nPola, a new LED product based on GaN-substrate technology that achieves over ten times the output of conventional LEDs.
For more information about Seoul Semiconductor, please visit http://www.seoulsemicon.com
# Trademarks: Wicop and Acrich are trademarks of Seoul Semiconductor Co., Ltd.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005266/en/
Contact:
Asia
Seoul Semiconductor Co., Ltd
Jake Jung, +82 070.4391.8270
Email:
pr@seoulsemicon.com
or
Europe
Seoul
Semiconductor Europe GmbH
Ariane Heim, +49 (0)89 450 3690-0
Email:
press.eu@seoulsemicon.com
or
North
America
Seoul Semiconductor Inc.
David Cox, +1 (919) 410-9856
Email:
David.cox@seoulsemicon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 08:50:00 CET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 08:30:00 CET | Press release
Based on DESTINY-Breast05 phase 3 trial results, which showed ENHERTU reduced the risk of invasive disease recurrence or death by 53% compared to T-DM1 If approved, Daiichi Sankyo and AstraZeneca’s ENHERTU has the potential to become a new standard of care in this early breast cancer setting The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committ
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 08:00:00 CET | Press release
The project confirms NHOA Energy’s long-term commitment to the Italian market NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 02:18:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Andersen Consulting udvider sine kompetencer inden for ledelsesrekruttering med Lansdowne Executive Search18.2.2026 17:08:00 CET | Pressemeddelelse
Andersen Consulting styrker sin humancapital-praksis gennem en samarbejdsaftale med Lansdowne Executive Search, der er en Dublin-baseret virksomhed med speciale i lederrekruttering, midlertidige ledelser og bestyrelsesudnævnelser. Lansdowne Executive Search er en irisk-ejet virksomhed, der blev grundlagt i 2015, og som tilbyder C-level-ledelsesekruttering, deltidsledere og bestyrelsesplaceringer. Som en partnerdrevet boutique-virksomhed er Lansdowne kendt for, at seniorledelsen er tæt involveret i alle kundeprojekter. Virksomheden hjælper kunder med at navigere i komplekse ledelsesovergange og vækststrategier på tværs af en bred vifte af sektorer, herunder finans, byggeindustrien, nonprofit, landbrug, videregående uddannelse, den offentlige sektor samt teknologi, medier og telekommunikation. "God ledelse er afhænger af situationen, og det kræver forståelse af langt mere end blot et CV," sagde Tom Keane, der er partner hos Lansdowne Executive Search. "Samarbejdet med Andersen Consulting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom